Advertisement

Anti-Inflammatory Drugs in the 21st Century

  • K.D. Rainsford
Part of the Subcellular Biochemistry book series (SCBI, volume 42)

Abstract

Historically, anti-inflammatory drugs had their originsin the serendipitous discovery of certain plants and their extracts being applied for the relief of pain, fever and inflammation. When salicylates were discovered in the mid-19th century to be the active components of Willow Spp., thisenabled these compounds to be synthesized and from this,acetyl-salicylic acid or Aspirin trademark was developed.Likewise, the chemical advances of the 19th–20th centuries leadto development of the non-steroidal anti-inflammatory drugs(NSAIDs), most of which were initially organic acids, but laternon-acidic compounds were discovered. There were two periods ofNSAID drug discovery post-World War 2, the period up to the 1970’swhich was the pre-prostaglandin period and thereafter up to the latter part of the last century in which their effects on prostaglandin production formed part of the screening in thedrug-discovery process. Those drugs developed up to the 1980-late90’s were largely discovered empirically following screening for anti-inflammatory, analgesic and antipyretic activities inlaboratory animal models. Some were successfully developed thatshowed low incidence of gastro-intestinal (GI) side effects (theprincipal adverse reaction seen with NSAIDs) than seen with their predecessors (e.g. aspirin, indomethacin, phenylbutazone); the GIreactions being detected and screened out in animal assays. In the1990’s an important discovery was made from elegant molecular andcellular biological studies that there are two cyclo-oxygenase(COX) enzyme systems controlling the production of prostanoids [prostaglandins (PGs) and thromboxane (TxA2) ]; COX-1that produces PGs and TxA2 that regulategastrointestinal, renal, vascular and other physiological functions, and COX-2 that regulates production of PGs involved in inflammation, pain and fever. The stage was set in the 1990’s forthe discovery and development of drugs to selectively controlCOX-2 and spare the COX-1 that is central to physiological processes whose inhibition was considered a major factor indevelopment of adverse reactions, including those in the GI tract.At the turn of this century, there was enormous commercialdevelopment following the introduction of two new highly selectiveCOX-2 inhibitors, known as coxibs (celecoxib and rofecoxib) whichwere claimed to have low GI side effects. While found to have fulfilled these aims in part, an alarming turn of events tookplace in the late 2004 period when rofecoxib was withdrawn worldwide because of serious cardiovascular events and other coxibs were subsequently suspected to have this adverse reaction, although to a varying degree. Major efforts are currently underwayto discover why cardiovascular reactions took place with coxibs, identify safer coxibs, as well as elucidate the roles of COX-2 andCOX-1 in cardiovascular diseases and stroke in the hope that there may be some basis for developing newer agents (e.g. nitricoxide-donating NSAIDs) to control these conditions

The discovery of the COX isoforms led to establishing their importance in many non-arthritic or non-pain states where there isan inflammatory component to pathogenesis, including cancer, Alzheimer’s and other neurode generative diseases. The applications of NSAIDs and the coxibs in the prevention and treatment of theseconditions as well as aspirin and other analogues in the prevention of thrombo-embolic diseases now constitute one of the major therapeutic developments of the this century. Moreover, new anti-inflammatory drugs are being discovered and developed based ontheir effects on signal transduction and as anti-cytokine agents andthese drugs are now being heralded as the new therapies to controlthose diseases where cytokines and other non-prostaglandin components of chronic inflammatory and neurode generative diseasesare manifest. To a lesser extent safer application ofcorticosteroids and the applications of novel drug delivery systemsfor use with these drugs as well as with NSAIDs also represent newer technological developments of the 21st century. What started out asdrugs to control inflammation, pain and fever in the last two centuries now has exploded to reveal an enormous range and type of anti-inflammatory agents and discovery of new therapeutic targets totreat a whole range of conditions that were never hitherto envisaged

Keywords

Actinic Keratosis Tiaprofenic Acid Tolfenamic Acid Signal Transduction Inhibitor Flunixin Meglumine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY; Group for the Respect of Excellence and Ethics in Science. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12:263–268.PubMedGoogle Scholar
  2. Adams SS, Cobb R. Non-steroidal anti-inflammatory drugs. In: Progress in Medicinal Chemistry, 5, GP Ellis, GB West, eds. London: Butterworth, 1967, 59–133.Google Scholar
  3. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:10–14.PubMedGoogle Scholar
  4. Ambrosini MV, Mariucci G, Rambotti MG, Tantucci M, Covarelli C, De Angelis L, Del Soldato P. Ultrastructural investigations onprotective effects of NCX 4016 (nitroaspirin) on macrovascular endothelium in diabetic Wistar rats. J Submicrosc Cytol Pathol. 2005;37:205–213.PubMedGoogle Scholar
  5. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB,cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006;30:45–51.PubMedGoogle Scholar
  6. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF. Bonedestruction by breast tumours. Prostaglandins. 1976;11:461–463.PubMedGoogle Scholar
  7. Bennett A. Prostaglandins as factors in diseases of the alimentary tract. Adv Prostaglandin Thromboxane Res. 1976;2:547–555.PubMedGoogle Scholar
  8. Bennett A, McDonals AM, Simpson JS, Stamford IF. Breast cancer,prostaglandins, and bone metastases. Lancet. 1975;31:1218–1220.Google Scholar
  9. Bennett A, Del Tacca M. Proceedings: Prostaglandins in human colonic carcinoma. Gut. 1975;16:409.PubMedGoogle Scholar
  10. Bennett A, Effects of kinins and prostaglandins on the gut. Proc RSoc Med. 1971;64:12–13.Google Scholar
  11. Bernstein S. Historic reflection on steroids: Lederle and personal aspects. Steroids. 1992;57:392–402.PubMedGoogle Scholar
  12. Bolos J. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Mini Rev Med Chem. 2005;5:857–868.PubMedGoogle Scholar
  13. Bolla M, Zoli W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines Apoptosis. 2006;11:1321–30.Google Scholar
  14. Brooks PM, Buchanan WW, Rosenbloom D, Bellamy N. Clinical efficacy and responses in therapy with anti-inflammatory and anti-rheumaticdrugs. In: Anti-Inflammatory and Anti-Rheumatic Drugs, Vol III: Anti-Rheumatic Drugs, Experimental Agents, and Clinical Aspects of Drug Use, K D Rainsford, ed. Boca Raton (Fl): CRC Press, 1985, 167–203.Google Scholar
  15. Bryant CE, Farnfield BA, Janicke HJ. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res. 2003;64:211–215.PubMedGoogle Scholar
  16. Celec P. Nuclear factor kappa B–molecular biomedicine: the next generation. Biomed Pharmacother. 2004;58:365–371.PubMedGoogle Scholar
  17. Chiroli V, Benedini F, Ongini E, Del Soldato P. Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case ofnitroderivatives of aspirin. Eur J Med Chem. 2003;38:441–446.PubMedGoogle Scholar
  18. Claria J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des. 2005;11:3431–3447.PubMedGoogle Scholar
  19. Corazzi T, Leone M, Roberti R, Del Soldato P, Gresele P. Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. Biochem Biophys Res Commun. 2003;311:897–903.PubMedGoogle Scholar
  20. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX4016). J Pharmacol Exp Ther. 2005;315:1331–1337.PubMedGoogle Scholar
  21. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005;84:291–302.Google Scholar
  22. Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol.2006;12:2884–2889.PubMedGoogle Scholar
  23. Damjanovic D, Thompson P, Findlay MP. Evidence-based update of chemotherapy options for metastatic colorectal cancer. ANZ J Surg. 2004;74:781–787.PubMedGoogle Scholar
  24. Dannhardt G, Laufer S. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? Curr Med Chem, 2000;7:11-1-1112.Google Scholar
  25. Dargent D. Utilization of tanderil during radium therapy of cancer of the female genital apparatus. Lyon Med. 1969;221:1261–1262.PubMedGoogle Scholar
  26. De Leval X, Delarge J, Somers F, de Tullio P, Henrotin Y, Pirotte B, Dognè J-M. Recent advances in inducible cyclooxygenase(COX-2) inhibition. Curr Med Chem. 2000;7:1041–1062.PubMedGoogle Scholar
  27. de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, Suzuki H, Mariotto S. STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem. 2005;12:1819–1828.PubMedGoogle Scholar
  28. Dhawan V, Schwalb DJ, Shumway MJ, Warren MC, Wexler RS, Zemtseva IS, Zifcak BM, Janero DR. Selective nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis. Free Radic Biol Med. 2005;39:1191–1207.PubMedGoogle Scholar
  29. Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem. 2005;5:953–965.PubMedGoogle Scholar
  30. Elhajj II, Haydar AA, Hujairi NM, Goldsmith DJ. The role of inflammation in acute coronary syndromes: review of the literature. J Med Liban. 2004;52:96–102.PubMedGoogle Scholar
  31. Evans D, Williamson WRN. Chemistry of clinically active anti-inflammatory compounds. In: Anti-Inflammatory Compounds. New York & Basel: Marcel Dekker, 1987, 193–302.Google Scholar
  32. Fabbri F, Brigliadori G, Ulivi P, Tesei A, Vannini I, Rosetti M, Bravaccini S, Amadori D, Bolla M, Zoli W. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinomacells. Apoptosis. 2005;10:1095–1103.PubMedGoogle Scholar
  33. Ferriera SH, Moncado S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature New Biology.y1971;231:237–239.Google Scholar
  34. Firuzi O, Pratico D. Coxibs and Alzheimer’s disease: should they stay or should they go? Ann Neurol. 2006;59:219–228.PubMedGoogle Scholar
  35. Flower RJ. Drugs which inhibit prostaglandin synthesis. Pharmacol Rev. 1974;26:33–67.PubMedGoogle Scholar
  36. Franzoso G. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 2006;13:712–729PubMedGoogle Scholar
  37. Friedmann Y, Shriki A, Bennett ER, Golos S, Diskin R, Marbach I, Bengal E, Engelberg D. JX401, a p38{alpha} inhibitor, containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast. Mol Pharmacol. 2006 Jul 17; [Epub ahead of print]Google Scholar
  38. Gao J, Kashfi K, Rigas B. In vitro metabolism of nitricoxide-donating aspirin: the effect of positional isomerism. JPharmacol Exp Ther. 2005;312:989–997.Google Scholar
  39. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S A. 2005;102:17207–17212.PubMedGoogle Scholar
  40. Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet 1972;2:932–933.PubMedGoogle Scholar
  41. Goodwin JS, Bankhurst AD, Messner RP. Suppression of T-cell mitogenesis by prostaglandin. Existence of a prostaglandin producing suppressor cell. J Exp. Med. 1977;146:1719–1734.PubMedGoogle Scholar
  42. Goodwin JS, Bankhurst AD, Murphy SA, Selinger DS, Messner RP, Williams RC Jr. Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin. J. CLin. Lab. Immunol. 1978;1:197–199.PubMedGoogle Scholar
  43. Goldstein DM, Alfredson T, Bertrand J, Browner MF, Clifford K, Dalrymple SA, Dunn J, Freire-Moar J, Harris S, Labadie SS, LaFargue J, Lapierre JM, Larrabee S, Li F, Papp E, McWeeney D, Ramesha C, Roberts R, Rotstein D, San Pablo B, Sjogren EB, So OY,Talamas FX, Tao W, Trejo A, Villasenor A, Welch M, Welch T, Weller P, Whiteley PE, Young K, Zipfel S. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)-phenyl]methanone(RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J Med Chem. 2006;49: 1562–1575.PubMedGoogle Scholar
  44. Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of P38MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem. 2005;5:1017–1029.PubMedGoogle Scholar
  45. Grzanna R, Lindmark L, Frondoza CG. Ginger–an herbal medicinal product with broad anti-inflammatory actions. J Med Food.y2005;8:125–32.PubMedGoogle Scholar
  46. Hall VC, Wolf RE. Effects of tenidap and non-steroidalanti-inflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis. J. Rheumatol. 1997;24:1467–1470.PubMedGoogle Scholar
  47. Harris M, Jenkins MV, Bennett A, Wills MR. Prostaglandin production and bone resorption by dental cysts. Nature. 1973;245: 213–215.PubMedGoogle Scholar
  48. Harris RE (ed.). COX-2 Blockade in Cancer Prevention and Therapy.lTotawa, NJ: Humana Press, 2002aGoogle Scholar
  49. Harris RE. Epidemiology of breast cancer and nonsteroidal anti-inflammatory drugs. In: COX-2 Blockade in Cancer Prevention and Therapy. R.E. Harris, ed. Totawa, NJ: HumanaPress, 2002b, 57–68.Google Scholar
  50. Hirschmann R. The cortisone era: aspects of its impact. Some contributions of the Merck Laboratories. Steroids.y1992;57:579–592.PubMedGoogle Scholar
  51. Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP, Chopin DK, Vacherot F. Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug(NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate. 2004a;61:132–141.PubMedGoogle Scholar
  52. Huguenin S, Vacherot F, Kheuang L, Fleury-Feith J, Jaurand MC, Bolla M, Riffaud JP, Chopin DK. Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donatingnon-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines. Mol Cancer Ther. 2004b;3:291–298.Google Scholar
  53. Hundley TR, Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J Pharmacol Exp Ther. 2006;316:25–34.PubMedGoogle Scholar
  54. Hynes J Jr, Leftheri K. Small molecule p38 inhibitors: novel structural features and advances from 2002–2005. Curr Top Med Chem. 2005;5:967–985PubMedGoogle Scholar
  55. Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding themolecular target repertoire of chemoprevention. Biochem Pharmacol. 2005;70:969–986.PubMedGoogle Scholar
  56. Jaffe BM, Parker CW, Philpott GW. Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultures tissue. Surg Forum. 1971;22:90–92.PubMedGoogle Scholar
  57. JForl J. Trial of Tandearil in prevention of cutaneous and mucosal complications in patients with otoshinolaryngeal neoplasms treatedby irradiation. Otorhinolaryngeal Audiophonol Chir Maxillofac.1976;25:175–178.Google Scholar
  58. Jiang C, Ting AT, Seed B. PPAR- γ agonists inhibit production of monokine inflammatory cytokines. Nature.1998;391:82–86.PubMedGoogle Scholar
  59. Jimi E, Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev. 2005;208:80–87.PubMedGoogle Scholar
  60. Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 2004;8 Suppl 3:13–21.PubMedGoogle Scholar
  61. Kaplan EL, Peskin GW. Physiologic implications of medullary carcinoma of the thyroid gland. Surg Clin North Am. 1971;51:125–137.PubMedGoogle Scholar
  62. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy–from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253–262.PubMedGoogle Scholar
  63. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol. 2005;39:557–569.PubMedGoogle Scholar
  64. Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology. 2005;13:343–370.PubMedGoogle Scholar
  65. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol. 2002;137: 295–310.PubMedGoogle Scholar
  66. Klein U, Muller-Fassbender H, Bublath H, Heinze HG. Effects of oxyphenbutazone on radiation fibrosis following irradiation for breast carcinoma. Strahlentherapie. 1972;144:421–429.PubMedGoogle Scholar
  67. Kopp E, Ghosh S. Inhibition of NFkappaB by sodium salicylate and aspirin. Science. 1994;265:956–959.PubMedGoogle Scholar
  68. Kulkarni RG, Achaiah G, Sastry GN. Novel targets for antiinflammatory and antiarthritic agents. Curr Pharm Des. 2006;12:2437–2454.PubMedGoogle Scholar
  69. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol. 2003;192:294–306.PubMedGoogle Scholar
  70. Levine L, Hinkle PM, Voelkel EF, Tashjian AH Jr. Prostaglandin production by moouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochem Biophys Res Commun. 1972;47: 888–896.PubMedGoogle Scholar
  71. Lin TH, Metzger A, Diller DJ, Desai M, Henderson I, Ahmed G, Kimble EF, Quadros E, Webb ML. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors. J Pharmacol Exp Ther. 2006;318:495–502.PubMedGoogle Scholar
  72. Lindahl F. Intestinal injuries following irradiation for carcinoma of the uterine cervix and vesical carcinoma. Acta Chir Scand. 1970;136:725–730.PubMedGoogle Scholar
  73. LiVolsi VA. Anti-metastatic effect of aspirin. Lancet. 1973;2:263.PubMedGoogle Scholar
  74. Lo CJ, Cryer HG, Fu M, Lo FR. Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappaB. J Trauma. 1998;45:19–23PubMedGoogle Scholar
  75. Makman MH. Conditions leading to enhanced response to glucagons,epinephrine, or prostaglandins by adenylate cyclase of normal and malignant cultured cells. Proc Natl Acad Sci USA. 1971;68: 2127–2130.PubMedGoogle Scholar
  76. Maulik N, Sato M, Price BD, Das DK. An essential role of NFkappaBin tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett. 1998;429:365–369.PubMedGoogle Scholar
  77. Metzger A, Diller DJ, Lin TH, Henderson I, Webb ML. Successful screening of large encoded combinatorial libraries leading to the discovery of novel p38 MAP kinase inhibitors. Comb Chem High Throughput Screen. 2006;9:351–358.PubMedGoogle Scholar
  78. Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-y1]-2-pyridyl]-benzamide(TAK-715) as a potent and orally active anti-rheumatoid arthritisagent. J Med Chem. 2005;48:5966–5979.PubMedGoogle Scholar
  79. Muller-Fassbender H, Klein U, Bablath H, Heinze HG. Effect of oxyphenbutazone on radiation-induced lung diseases. Med Klin. 1973; 68:478–483.PubMedGoogle Scholar
  80. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii74–7.Google Scholar
  81. Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol. 2004;57:6–13.PubMedGoogle Scholar
  82. O’Brien JR. Effects of salicylates on human platelets. Lancet. 1968; 1(4546), 779–783.PubMedGoogle Scholar
  83. Otterness IG. The discovery of drugs to treat arthritis. A historical view. In: The Search for Anti-inflammatory Drugs. VJ Merluzzi, J. Adams, eds. Boston: Birkhäuser, 1995, 1–26.Google Scholar
  84. Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem. 2000;275:28173–28179.PubMedGoogle Scholar
  85. Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, Dean K, Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem. 2006;6:113–149.Google Scholar
  86. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets. 2006;5:91–106.PubMedGoogle Scholar
  87. Paulus HE. Clinical trial design for evaluating combination therapies. Br J Rheumatol. 1995;34 Suppl 2:92–95PubMedGoogle Scholar
  88. Pellegatta F, Bertelli AA, Staels B, Duhem C, Fulgenzi A, FerreroME. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am J Clin Nutr. 2003;77:1220–1228.PubMedGoogle Scholar
  89. Petasis NA, Akritopoulou-Zanze I, Fokin VV, Bernasconi G, Keledjian R, Yang R, Uddin J, Nagulapalli KC, Serhan CN. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent FattyAcids. 2005;73:301–321.Google Scholar
  90. Phillips T, Leeuwenburgh C. Lifelong aspirin supplementation as a means to extending life span. Rejuvenation Res. 2004 Winter;7(4):243–51.Google Scholar
  91. Powles TJ, Easty DM, Easty GC, Neville AM. Tumor-induced osteolysis. N Engl J Med. 1974;291:105.PubMedGoogle Scholar
  92. Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer. 1973;28:316–321.PubMedGoogle Scholar
  93. Powles TJ, Easty GC, Easty DM, Neville AM. Anti-metastatic effect of aspirin. Lancet. 1973;2:100.PubMedGoogle Scholar
  94. Prescott LF. Paracetamol (Acetaminiphen). A Critical Bibliographic Review. Revised 2nd Edn. London: Taylor & Francis, 2001.Google Scholar
  95. Rainsford KD. History and development of ibuprofen. In: Ibuprofen. A Critical Bibliographic Review, K.D. Rainsford, ed. London: Taylor & Francis, 1999a, 1–24.Google Scholar
  96. Rainsford KD. Pharmacology and toxicology of ibuprofen. In: Ibuprofen. A Critical Bibliographic Review, K.D. Rainsford, ed. London: Taylor & Francis, 1999b, 145–275.Google Scholar
  97. Rainsford KD. History and development of the salicylates. In: Aspirin and Related Drugs, K.D. Rainsford, ed. London & New York: Taylor & Francis, 2004a, 1–23.Google Scholar
  98. Rainsford KD. Side effects and toxicology of the salicylates. In:Aspirin and Related Drugs, K.D. Rainsford, ed. London &New York: Taylor and Francis, 2004b, 367–554.Google Scholar
  99. Rainsford KD. Pharmacology and Biochemistry of salicylates and related drugs. In: Aspirin and Related Drugs, K.D.Rainsford, ed. London and New York: Taylor & Francis, 2004c,215–366.Google Scholar
  100. Rainsford KD. Aspirin and NSAIDs in the prevention of cancer, Alzheimer’s disease and othe novel therapeutic actions. In: Aspirin and Related Drugs, K.D. Rainsford, ed. London and NewYork: Taylor & Francis, 2004d, 707–756.Google Scholar
  101. Rainsford KD. Inhibitors of eicosanoids. In: The Eicosanoids, P Curtis-Prior, ed. Chichester: John Wiley &Sons, 2004e, 189–210.Google Scholar
  102. Rainsford KD. Occurrence, properties and synthetic developments ofthe salicylates. In: Aspirin and Related Drugs, K.D.Rainsford, ed. London & New York: Taylor & Francis, 2004f,45–95.Google Scholar
  103. Rainsford KD. Aspirin and NSAIDs in the prevention of cancer, Alzheimer’s disease and other novel therapeutic actions. In: Aspirin and Related Drugs, K.D. Rainsford, ed. London & NewYork: Taylor & Francis, 2004g, 707–756.Google Scholar
  104. Rainsford KD. The discovery, development and novel actions of nimesulide. In: Nimesulide – Actions and Uses, K.D.Rainsford, ed. Basel: Birkhäuser Verlag, 2005a, 1–61.Google Scholar
  105. Rainsford KD. The coxib controversies. Inflammopharmacology. 2005b;13:331–341.Google Scholar
  106. Riedl K, Krysan K, Pold M, Dalwadi H, Heuze-Vourc’h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett SM. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat. 2004;7:169–184.PubMedGoogle Scholar
  107. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med. 2005;56:225–248.PubMedGoogle Scholar
  108. Rigas B, Kalofonos H, Lebovics E, Vagenakis AG. NO-NSAIDs and cancer: promising novel agents. Dig Liver Dis. 2003;35 Suppl2:S27–34.PubMedGoogle Scholar
  109. Rocha PN, Plumb TJ, Coffman TM. Eicosanoids: lipid mediators of inflammation in transplantation. Springer Semin Immunopathol. 2003;25:215–227.PubMedGoogle Scholar
  110. Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets. 2004;5:535–551.PubMedGoogle Scholar
  111. Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res. 2006;66:4503–4511.Google Scholar
  112. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol. 2004;172:338–344.PubMedGoogle Scholar
  113. Russo-Marie F. Antiinflammatory steroids. In: The Eicosanoids. P. Curtis-Prior, ed. Chichester: John Wiley &Sons, 2004, 327–332.Google Scholar
  114. Sabat M, Vanrens JC, Clark MP, Brugel TA, Maier J, Bookland RG, Laufersweiler MJ, Laughlin SK, Golebiowski A, De B, Hsieh LC, Walter RL, Mekel MJ, Janusz MJ. The development of novel C-2, C-8,and N-9 trisubstituted purines as inhibitors of TNF-alphaproduction. Bioorg Med Chem Lett. 2006;16:4360–4365.PubMedGoogle Scholar
  115. Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer. 2004;11(2):129–133.PubMedGoogle Scholar
  116. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004;4:372–377.PubMedGoogle Scholar
  117. Sanborn R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin Oncol. 2005;32:69–75.PubMedGoogle Scholar
  118. Sandler M, Karim SM, Williams ED. Prostaglandins in amine-peptide-secreting tumours. Lancet. 1968;2:1053–1054.PubMedGoogle Scholar
  119. Serhan CN. Novel eicosanoid and docosanoid mediators: resolvins,docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care. 2005;8:115–121.PubMedGoogle Scholar
  120. Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes,and neuroprotectins, novel omega-3-derived mediators,and their endogenous aspirin-triggered epimers. Lipids. 2004;39:1125–1132.PubMedGoogle Scholar
  121. Shay NF, Banz WJ. Regulation of gene transcription by botanicals:novel regulatory mechanisms. Annu Rev Nutr. 2005;25:297–315.PubMedGoogle Scholar
  122. Simon LS. The treatment of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004;18:507–538.PubMedGoogle Scholar
  123. Skinner R. Role of topical therapies in the management of cutaneous disease. J Cutan Med Surg. 2004;8 Suppl 3:22–31.PubMedGoogle Scholar
  124. Smith JW, Steiner AL, Parker CW. Human lymphocyte metabolism. Effects of cyclic and non-cyclic nucleotides, on stimulation by phytohaemagglutinin. J.Clin. Invest. 1971;50:442–448.PubMedGoogle Scholar
  125. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.PubMedGoogle Scholar
  126. Trummlitz G, van Ryn J. Designing selective COX-2 inhibitors: molecular modeling approaches. Curr Opin Drug Discov Devel. 2002;5:550–561.PubMedGoogle Scholar
  127. Thun MJ, Henley SJ. Epidemiology of nonsteroidal anti-inflammatory drugs and colorectal cancer. In: COX-2 Blockade in Cancer Prevention and Therapy. R.E. Harris, ed. Totawa, NJ: Humana Press,2002; 35–55.Google Scholar
  128. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biology.1971;231:232–235.PubMedGoogle Scholar
  129. Van Wijk R, Wicks WD, Clay, K. Effects of derivatives of cyclic 3′,5′ -adenosine monophosphate on the growth, morphology, and gene expression of hepatoma cells in culture. Cancer Res. 1972;32: 1905–1911.Google Scholar
  130. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997;11:1245–1255.PubMedGoogle Scholar
  131. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55:115–122.PubMedGoogle Scholar
  132. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology. 2004;43 (Suppl 3):iii17-iii23.PubMedGoogle Scholar
  133. Webert KE, Kelton JG. Acetylsalicylic acid for prevention and treatment of thromboembolic diseases. In: Aspirin and Related Drugs, K.D. Rainsford, ed. London & New York: Taylor &Francis, 619–633.Google Scholar
  134. Whittle BJ. Nitric oxide and the gut injury induced by non-steroidal anti-inflammatory drugs. Inflammopharmacology. 2003;11:415–422.PubMedGoogle Scholar
  135. Wood S Jr, Hilgard P. Aspirin and tumour metastasis. Lancet. 1972;2:1416–1417.PubMedGoogle Scholar
  136. Wu KK. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids. 2005;72:89–93.PubMedGoogle Scholar
  137. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005 Jul 25;1755(2):135–150.Google Scholar
  138. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiacischemia/reperfusion. J Surg Res. 2005;125:109–116.PubMedGoogle Scholar
  139. Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46:585–596.PubMedGoogle Scholar
  140. Yoon JB, Kim SJ, Hwang SG, Chang S, Kang SS, Chun JS. Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity. J Biol Chem. 2003;278:15319–15325.PubMedGoogle Scholar
  141. Zacharowski P, Zacharowski K, Donnellan C, Johnston A, Vojnovic I, Forte P, Del Soldato P, Benjamin N, O’Byrne S. The effects and metabolic fate of nitroflurbiprofen in healthy volunteers. Clin Pharmacol Ther. 2004;76:350–358.PubMedGoogle Scholar
  142. Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res. 2004;26:884–892.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • K.D. Rainsford
    • 1
  1. 1.Biomedical Research CentreSheffield Hallam UniversitySheffieldUK

Personalised recommendations